Inventor · disambiguated record
Xiumei Cai
Also filed as: CAI XIUMEI
6 granted patents·3 pending applications·8 citations·filing 2015–2024
74Inventor score
Files withSHANGHAI YILE BIOTECHNOLOGY CO LTD4CRAGE MEDICAL CO LTD3CAFA THERAPEUTICS LTD1CARSGEN THERAPEUTICS LTD1
Top patents by PatentIndex Score
9 records- 0187US10377822B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCARSGEN THERAPEUTICS LTD·Filed 2015·Granted Aug 13, 2019·5 cites·13 claims
- 0285US11198729B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Granted Dec 14, 2021·3 cites·11 claims
- 0383US2025230232A1Immunologic effector cell of targeted cld18a2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2024·Application pending·0 cites
- 0475US12098199B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCRAGE MEDICAL CO LTD·Filed 2021·Granted Sep 24, 2024·0 cites·10 claims
- 0550US2021017264A1Use of binding molecule specifically binding to precursor of brain-derived neurotrophic factorSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
- 0648US10556947B2Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factorSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2017·Granted Feb 11, 2020·0 cites·17 claims
- 0742US2022064274A1Use of probdnf regulator in b cell-related diseasesSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2019·Application pending·0 cites
- 0838US11479603B2Polypeptide and antibody bound to polypeptideSHANGHAI YILE BIOTECHNOLOGY CO LTD·Filed 2018·Granted Oct 25, 2022·0 cites·5 claims
- 0935US11453860B2GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereofCRAGE MEDICAL CO LTD·Filed 2015·Granted Sep 27, 2022·0 cites·11 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →